Travere Therapeutics (TVTX) Stock Forecast & Price Target

Compare

574 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TVTX Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Travere

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TVTX Stock 12 Month Forecast

Average Price Target

$41.73

▲(49.73% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $41.73 with a high forecast of $49.00 and a low forecast of $31.00. The average price target represents a 49.73% change from the last price of $27.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","50":"$50","22.25":"$22.3","31.5":"$31.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,22.25,31.5,40.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.21,39.04,39.87,40.7,41.53,42.36,43.19,44.02,44.85,45.68,46.51,47.34,48.17,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.21,38.48076923076923,38.75153846153846,39.02230769230769,39.293076923076924,39.56384615384615,39.83461538461538,40.105384615384615,40.37615384615385,40.64692307692307,40.917692307692306,41.18846153846154,41.459230769230764,{"y":41.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.21,37.65538461538462,37.10076923076923,36.54615384615385,35.99153846153846,35.43692307692308,34.88230769230769,34.32769230769231,33.77307692307692,33.21846153846154,32.66384615384615,32.10923076923077,31.554615384615385,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.21,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$49.00

Average Price Target$41.73

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Chico

Wedbush

$37

Buy

32.76%

Upside

Reiterated

01/14/26

Wedbush Remains a Buy on Travere Therapeutics (TVTX)

Alex Thompson CFA

Stifel Nicolaus

$31

Hold

11.23%

Upside

Reiterated

01/13/26

Travere Therapeutics (TVTX) Gets a Hold from Stifel Nicolaus

Joseph Schwartz

Leerink Partners

Buy

―

Reiterated

01/13/26

Leerink says Travere's Filspari PDUFA extension removes worst case scenario Leerink says Travere's Filspari PDUFA extension removes worst case scenario

Tyler Van Buren

TD Cowen

$30→$40

Buy

43.52%

Upside

Reiterated

01/13/26

Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX)

Jason Zemansky

Bank of America Securities

$47→$43

Buy

54.29%

Upside

Reiterated

01/13/26

Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Gavin Clark-Gartner

Evercore ISI

$42

Buy

50.70%

Upside

Reiterated

01/13/26

Evercore ISI Remains a Buy on Travere Therapeutics (TVTX)

Vamil Divan

Guggenheim

$49

Buy

75.82%

Upside

Reiterated

01/13/26

Guggenheim Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

Mohit Bansal

Wells Fargo

$40

Buy

43.52%

Upside

Reiterated

01/13/26

Wells Fargo Remains a Buy on Travere Therapeutics (TVTX)

Joseph Pantginis

H.C. Wainwright

$47

Buy

68.64%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Travere Therapeutics (NASDAQ: TVTX) and Beyond Air (NASDAQ: XAIR)

Yigal Nochomovitz

Citi

$48

Buy

72.23%

Upside

Assigned

01/13/26

Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset

Edward Nash

Canaccord Genuity

$47

Buy

68.64%

Upside

Reiterated

01/12/26

Canaccord Genuity Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

11/07/25

Optimistic Buy Rating for Travere Therapeutics Driven by Filspari's Market Potential and Strategic Positioning

Allison Bratzel

Piper Sandler

$26→$35

Hold

25.58%

Upside

Reiterated

11/04/25

Travere Therapeutics price target raised to $35 from $26 at Piper SandlerTravere Therapeutics price target raised to $35 from $26 at Piper Sandler

Maury Raycroft

Jefferies

$35

Buy

25.58%

Upside

Reiterated

09/10/25

AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

09/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Chico

Wedbush

$37

Buy

32.76%

Upside

Reiterated

01/14/26

Wedbush Remains a Buy on Travere Therapeutics (TVTX)

Alex Thompson CFA

Stifel Nicolaus

$31

Hold

11.23%

Upside

Reiterated

01/13/26

Travere Therapeutics (TVTX) Gets a Hold from Stifel Nicolaus

Joseph Schwartz

Leerink Partners

Buy

―

Reiterated

01/13/26

Leerink says Travere's Filspari PDUFA extension removes worst case scenario Leerink says Travere's Filspari PDUFA extension removes worst case scenario

Tyler Van Buren

TD Cowen

$30→$40

Buy

43.52%

Upside

Reiterated

01/13/26

Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX)

Jason Zemansky

Bank of America Securities

$47→$43

Buy

54.29%

Upside

Reiterated

01/13/26

Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Gavin Clark-Gartner

Evercore ISI

$42

Buy

50.70%

Upside

Reiterated

01/13/26

Evercore ISI Remains a Buy on Travere Therapeutics (TVTX)

Vamil Divan

Guggenheim

$49

Buy

75.82%

Upside

Reiterated

01/13/26

Guggenheim Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

Mohit Bansal

Wells Fargo

$40

Buy

43.52%

Upside

Reiterated

01/13/26

Wells Fargo Remains a Buy on Travere Therapeutics (TVTX)

Joseph Pantginis

H.C. Wainwright

$47

Buy

68.64%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Travere Therapeutics (NASDAQ: TVTX) and Beyond Air (NASDAQ: XAIR)

Yigal Nochomovitz

Citi

$48

Buy

72.23%

Upside

Assigned

01/13/26

Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset

Edward Nash

Canaccord Genuity

$47

Buy

68.64%

Upside

Reiterated

01/12/26

Canaccord Genuity Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

11/07/25

Optimistic Buy Rating for Travere Therapeutics Driven by Filspari's Market Potential and Strategic Positioning

Allison Bratzel

Piper Sandler

$26→$35

Hold

25.58%

Upside

Reiterated

11/04/25

Travere Therapeutics price target raised to $35 from $26 at Piper SandlerTravere Therapeutics price target raised to $35 from $26 at Piper Sandler

Maury Raycroft

Jefferies

$35

Buy

25.58%

Upside

Reiterated

09/10/25

AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

09/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Travere Therapeutics

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+28.31%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +28.31% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

13/15 ratings generated profit

Average Return

+66.47%

reiterated a buy rating 6 days ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +66.47% per trade.

2 Years

xxx

Success Rate

14/15 ratings generated profit

Average Return

+122.87%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +122.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TVTX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TVTX has received 23 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. TVTX average Analyst price target in the past 3 months is 41.73.

Each month's total comprises the sum of three months' worth of ratings.

TVTX Financial Forecast

TVTX Earnings Forecast

Next quarter’s earnings estimate for TVTX is -$0.04 with a range of -$0.31 to $0.45. The previous quarter’s EPS was $0.28. TVTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TVTX has Performed in-line its overall industry.

TVTX Sales Forecast

Next quarter’s sales forecast for TVTX is $145.23M with a range of $122.37M to $188.37M. The previous quarter’s sales results were $164.86M. TVTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TVTX has Performed in-line its overall industry.

TVTX Stock Forecast FAQ

What is TVTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Travere Therapeutics’s 12-month average price target is 41.73.

What is TVTX’s upside potential, based on the analysts’ average price target?

Travere Therapeutics has 49.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TVTX a Buy, Sell or Hold?

Travere Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Travere Therapeutics’s price target?

The average price target for Travere Therapeutics is 41.73. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $49.00 ,the lowest forecast is $31.00. The average price target represents 49.73% Increase from the current price of $27.87.

What do analysts say about Travere Therapeutics?

Travere Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of TVTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Travere Therapeutics (TVTX) Stock Forecast & Price Target

TVTX Analyst Ratings

TVTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Travere Therapeutics

TVTX Analyst Recommendation Trends

TVTX Financial Forecast

TVTX Earnings Forecast

TVTX Sales Forecast

TVTX Stock Forecast FAQ

Detailed List of Analyst Forecasts